HC Wainwright & Co. Maintains Buy on TriSalus Life Sciences, Raises Price Target to $12
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains TriSalus Life Sciences (NASDAQ:TLSI) with a Buy and raises the price target from $11 to $12.
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains TriSalus Life Sciences (NASDAQ:TLSI) with a Buy and raises the price target from $11 to $12.